Inhaler is the first generic approval of its kind.
Formulary Watch
Latest News
All News
Advertisement
Express Scripts’ annual Drug Trend Report highlights top contributors to prescription drug spending in 2019.
Treatment is first non-statin LDL-C lowering treatment approved in years.
Eisai disagrees with FDA decision.
Treatments include meds for arthritis pain and allergy eye drops.
Treatment will be first to target a specific type of advanced lung cancer.
FDA cleared the first generic sodium iodide product to treat hyperthyroidism and carcinoma of the thyroid.
FDA's Center for Drug Evaluation and Research approved fewer new treatments in 2019.
Global market for peanut allergy treatments estimate at $4.5 billion.
A new class of drugs for high cholesterol and a novel peanut allergy treatment lead expected approvals.
Advertisement
Novel cancer drug snags FDA approval.
Traditional party drug known as ecstasy is undergoing clinical trials to assist in PTSD treatment.
Lamotrigine was contaminated with a heart drug.
Ozempic’s approval follows Jardiance’s expanded heart indication last July.
Already approved for adult patients, Fiasp is now available for children.
Major depression drug recalled over wrong dosage.
Pfizer bucks the trend with as high as 98.5% price cuts.
Approval of Ubrelvy follows several new migraine drugs.
Diabetes and hypertension are among the primary diseases included.
The fish oil drug is approved to reduce cardiovascular risk.
Alkermes omitted warnings about serious risks from taking the drug.
Stephen Hahn is confirmed by the U.S. Senate.
Hospitals sue over drug price disclosure rule.
This is the agency’s first generic approvals of Gilenya.
Approval made via international collaborative effort.
Federal subpoenas are latest in opioid actions.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
FDA approves first postmenopausal libido treatment, Addyi
2
What IRA drug prices will mean for PBMs, health plans and patients
3
Looking ahead: What the MHE 2025 State of the Industry survey tells us about 2026
4
Biosimilars in 2025: A year of firsts
5
